Lv11
34 积分 2024-09-03 加入
Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis
55分钟前
已完结
Single-institution experience with efgartigimod in patients with GFAP astrocytopathy: Treatment response and adverse events
10天前
已完结
Efgartigimod as adjunctive therapy in refractory autoimmune glial fibrillary acidic protein astrocytopathy: a case series
10天前
已完结
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
21天前
已完结
Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study
22天前
已完结
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study
23天前
已完结
Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis
24天前
已完结
Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis
4个月前
已完结
The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis
4个月前
已完结
Dispersion of mean consecutive differences in single‐fiber electromyography increases diagnostic sensitivity for myasthenia gravis
4个月前
已完结
皖公网安备34019202002308
